JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parker, E. M.
Right arrow Articles by Cubeddu, L. X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parker, E. M.
Right arrow Articles by Cubeddu, L. X.

Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding

EM Parker and LX Cubeddu

Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill.

We quantified the effects amphetamine (AMPH), phenylethylamine (PEA), tyramine (TYR), octopamine (OCT) and DA, on initial rates of DA uptake (striatal minces), binding of [3H]mazindol to the neuronal uptake (NU) site (striatal membranes) and on DA and dihydroxyphenylacetic acid (DOPAC) efflux (striatal slices). In general, the order of potency for the three paradigms was: AMPH less than DA = TYR = PEA less than OCT. The Km values for uptake were positively correlated with the Ki values for inhibition of mazindol binding (r = 0.91; P less than .01) and with the potencies to induce DA efflux (r = 0.96; P less than .005). Potencies for inhibition of mazindol binding and for eliciting DA efflux also were highly correlated (r = 0.92; P less than .01). Correlations were lost if data for nomifensine (NOM), a NU inhibitor, were included in the analysis. Despite the significant correlations, AMPH, TYR, PEA and OCT Despite the significant correlations, AMPH, TYR, PEA, and OCT were 10 to 20 times more potent in inhibiting NU than in eliciting efflux or inhibiting mazindol binding. Conversely, the potency of NOM to inhibit mazindol binding was 10 and 800 times greater than that required to inhibit NU or to elicit DA release, respectively. NOM inhibited competitively AMPH-induced DA release. These results suggest that: 1) AMPH-like drugs bind to and are likely to be transported by the NU carrier, and 2) inward transport of these agents appears to have multiple effects (e.g., an increase in intracellular Na+ and Cl-) that act cooperatively to increase Vmax and reduce Km for the outward, carrier-mediated DA transport. AMPH, TYR, PEA and OCT had qualitatively similar effects on endogenous DA and [3H]DA release. Monoamine oxidase inhibition potentiated these effects. All these agents released more endogenous DA from control than from reserpine- treated slices. In control slices, TYR and OCT increased DA and DOPAC efflux; whereas AMPH and PEA increased DA and reduced DOPAC efflux, except at high concentrations in which DOPAC efflux also was increased. After reserpine, these agents reduced DOPAC efflux in proportion to the increased DA efflux. In summary, we propose that AMPH-like drugs increase DA efflux from a single cytoplasmic pool maintained by DA synthesis and spontaneous and drug-induced efflux of DA from storage vesicles.(ABSTRACT TRUNCATED AT 400 WORDS)

Volume 245, Issue 1, pp. 199-210, 04/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
Z. Xie and G. M. Miller
{beta}-Phenylethylamine Alters Monoamine Transporter Function via Trace Amine-Associated Receptor 1: Implication for Modulatory Roles of Trace Amines in Brain
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 617 - 628.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. Lindemann, C. A. Meyer, K. Jeanneau, A. Bradaia, L. Ozmen, H. Bluethmann, B. Bettler, J. G. Wettstein, E. Borroni, J.-L. Moreau, et al.
Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 948 - 956.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. H. Cole, G. E. Carney, C. A. McClung, S. S. Willard, B. J. Taylor, and J. Hirsh
Two Functional but Noncomplementing Drosophila Tyrosine Decarboxylase Genes: DISTINCT ROLES FOR NEURAL TYRAMINE AND OCTOPAMINE IN FEMALE FERTILITY
J. Biol. Chem., April 15, 2005; 280(15): 14948 - 14955.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Federici, R. Geracitano, A. Tozzi, P. Longone, S. Di Angelantonio, C. P. Bengtson, G. Bernardi, and N. B. Mercuri
Trace Amines Depress GABAB Response in Dopaminergic Neurons by Inhibiting G-{beta}{gamma}-Gated Inwardly Rectifying Potassium Channels
Mol. Pharmacol., April 1, 2005; 67(4): 1283 - 1290.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Y. Schmitz, C. J. Lee, C. Schmauss, F. Gonon, and D. Sulzer
Amphetamine Distorts Stimulation-Dependent Dopamine Overflow: Effects on D2 Autoreceptors, Transporters, and Synaptic Vesicle Stores
J. Neurosci., August 15, 2001; 21(16): 5916 - 5924.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. T. Premont, R. R. Gainetdinov, and M. G. Caron
Following the trace of elusive amines
PNAS, August 14, 2001; 98(17): 9474 - 9475.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics.